ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
BRPI9910332B8
(pt)
|
1998-05-06 |
2021-05-25 |
Genentech Inc |
método para purificação de um polipeptídio a partir de uma composição
|
EP1500661A1
(de)
|
1998-06-01 |
2005-01-26 |
Genetech, Inc. |
Trennung von Protein-Monomeren von Aggregaten mittels Ionaustausch-Chromatographie
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
US6790709B2
(en)
*
|
2001-11-30 |
2004-09-14 |
Intel Corporation |
Backside metallization on microelectronic dice having beveled sides for effective thermal contact with heat dissipation devices
|
AU2002351353A1
(en)
|
2001-12-19 |
2003-09-02 |
Genentech, Inc. |
Stabilizing polypeptides which have been exposed to urea
|
FR2840695B1
(fr)
*
|
2002-06-07 |
2004-10-08 |
Chevrillon Philippe Ind |
Procede de fabrication de ceintures d'impression
|
US7998705B2
(en)
*
|
2002-08-06 |
2011-08-16 |
FUJIFILM Diosynth Biotechnologies U.S.A., Inc |
Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
|
HUE033623T2
(en)
*
|
2002-09-11 |
2017-12-28 |
Genentech Inc |
protein purification
|
TWI476206B
(zh)
*
|
2003-07-18 |
2015-03-11 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
US9259573B2
(en)
|
2003-10-15 |
2016-02-16 |
Rmx, Llc |
Device and method for manipulating exhalation
|
US7970475B2
(en)
|
2003-10-15 |
2011-06-28 |
Rmx, Llc |
Device and method for biasing lung volume
|
US7979128B2
(en)
|
2003-10-15 |
2011-07-12 |
Rmx, Llc |
Device and method for gradually controlling breathing
|
US8467876B2
(en)
|
2003-10-15 |
2013-06-18 |
Rmx, Llc |
Breathing disorder detection and therapy delivery device and method
|
US8160711B2
(en)
|
2003-10-15 |
2012-04-17 |
Rmx, Llc |
Multimode device and method for controlling breathing
|
US8265759B2
(en)
|
2003-10-15 |
2012-09-11 |
Rmx, Llc |
Device and method for treating disorders of the cardiovascular system or heart
|
US8140164B2
(en)
|
2003-10-15 |
2012-03-20 |
Rmx, Llc |
Therapeutic diaphragm stimulation device and method
|
US8244358B2
(en)
|
2003-10-15 |
2012-08-14 |
Rmx, Llc |
Device and method for treating obstructive sleep apnea
|
RS58420B1
(sr)
|
2003-11-05 |
2019-04-30 |
Roche Glycart Ag |
Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
EP1720536B1
(de)
|
2004-02-06 |
2012-04-25 |
PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST |
Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
|
US20060234907A1
(en)
*
|
2004-02-13 |
2006-10-19 |
Werner Gehringer |
Albumin solution and process for the production thereof
|
US7713629B2
(en)
|
2004-03-26 |
2010-05-11 |
Florida State University Research Foundation |
Hydrophobic fluorinated polyelectrolyte complex films and associated methods
|
US9056125B2
(en)
|
2004-05-17 |
2015-06-16 |
Florida State University Research Foundation, Inc. |
Films for controlled cell growth and adhesion
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
KR20070038557A
(ko)
*
|
2004-07-22 |
2007-04-10 |
제넨테크, 인크. |
Her2 항체 조성물
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008523073A
(ja)
*
|
2004-12-07 |
2008-07-03 |
ジェネンテック・インコーポレーテッド |
Her阻害剤を用いた治療のための患者の選択
|
ZA200706017B
(en)
|
2005-01-21 |
2008-12-31 |
Genentech Inc |
Fixed dosing of her antibodies
|
JP2008530123A
(ja)
*
|
2005-02-09 |
2008-08-07 |
ジェネンテック・インコーポレーテッド |
マトリックスメタロプロテアーゼアンタゴニストを用いたher2のシェディングの阻害
|
EP1850874B1
(de)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
|
US7585955B2
(en)
*
|
2005-03-03 |
2009-09-08 |
Florida State University Research Foundation, Inc |
Protein separation from a protein mixture
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
US7459542B2
(en)
*
|
2005-03-10 |
2008-12-02 |
Florida State University Research Foundation, Inc. |
Separation of albumin from protein samples
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
TWI320788B
(en)
|
2005-05-25 |
2010-02-21 |
Hoffmann La Roche |
Method for the purification of antibodies
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
US8921344B2
(en)
|
2006-11-03 |
2014-12-30 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
US7452872B2
(en)
|
2005-08-24 |
2008-11-18 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
SG170837A1
(en)
*
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
CN101627117B
(zh)
*
|
2006-08-01 |
2013-10-30 |
奇尼塔二有限责任公司 |
医药制造方法
|
EP2061802A1
(de)
*
|
2006-08-28 |
2009-05-27 |
Ares Trading S.A. |
Verfahren zur aufreinigung von fc-fusionsproteinen
|
FI2061803T4
(fi)
*
|
2006-08-28 |
2023-03-14 |
|
Process for the purification of fc-containing proteins
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
TW201516149A
(zh)
|
2006-09-13 |
2015-05-01 |
Abbvie Inc |
細胞培養改良
|
US8280513B2
(en)
|
2006-12-22 |
2012-10-02 |
Rmx, Llc |
Device and method to treat flow limitations
|
AU2008209404B2
(en)
*
|
2007-01-22 |
2012-08-16 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
MX2009008981A
(es)
*
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
AU2008256411B2
(en)
*
|
2007-06-01 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Immunoglobulin purification
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
AU2012227163B2
(en)
*
|
2007-10-30 |
2015-07-16 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
SG175597A1
(en)
*
|
2007-10-30 |
2011-11-28 |
Genentech Inc |
Antibody purification by cation exchange chromatography
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
WO2009088805A2
(en)
|
2008-01-03 |
2009-07-16 |
The Scripps Research Institute |
Antibody targeting through a modular recognition domain
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
UA127472C2
(uk)
|
2008-03-18 |
2023-09-06 |
Дженентек, Інк. |
Комбінація кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичного засобу і спосіб застосування
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2297208A4
(de)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
NZ589434A
(en)
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
ES2527943T5
(es)
|
2008-08-14 |
2019-03-07 |
Genentech Inc |
Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
AU2008221604B2
(en)
|
2008-09-22 |
2010-04-22 |
Commonwealth Scientific And Industrial Research Organisation |
Temperature-responsive polymer particles in protein separation applications
|
PE20110707A1
(es)
|
2008-10-14 |
2011-10-11 |
Genentech Inc |
Variantes de inmunoglobulinas
|
JP5808249B2
(ja)
*
|
2008-10-20 |
2015-11-10 |
アッヴィ・インコーポレイテッド |
プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製
|
CN104974251A
(zh)
|
2008-10-20 |
2015-10-14 |
Abbvie公司 |
在抗体纯化过程中的病毒灭活
|
MX2011004558A
(es)
|
2008-10-29 |
2011-06-01 |
Wyeth Llc |
Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
|
EP2400984A4
(de)
*
|
2009-02-25 |
2013-01-23 |
Merck Sharp & Dohme |
Her2-antikörperzusammensetzungen
|
TWI461211B
(zh)
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
WO2010126979A1
(en)
*
|
2009-04-29 |
2010-11-04 |
Bio-Rad Laboratories, Inc. |
Purification of immunoconjugates
|
EP2435071A1
(de)
|
2009-05-29 |
2012-04-04 |
F. Hoffmann-La Roche AG |
Modulatoren für den her2-signalweg bei her2-exprimierenden patienten mit magenkrebs
|
CN102471377B
(zh)
|
2009-07-24 |
2015-04-22 |
霍夫曼-拉罗奇有限公司 |
优化抗体的生产
|
CA2766836A1
(en)
|
2009-07-24 |
2011-01-27 |
F. Hoffmann-La Roche Ag |
Stirrer system
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
CN106008697B
(zh)
*
|
2009-08-20 |
2020-08-04 |
百深公司 |
纯化vwf以增加非-脂质包封的病毒的去除
|
BR112012004710A2
(pt)
|
2009-09-01 |
2016-08-16 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e uso das mesmas
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
MX342442B
(es)
|
2009-10-01 |
2016-09-29 |
F Hoffmann-La Roche Ag * |
Filtracion final en multiples pasos.
|
MX2012004415A
(es)
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US8304248B2
(en)
*
|
2009-11-16 |
2012-11-06 |
Torres Anthony R |
Protein separation via ion-exchange chromatography and associated methods, systems, and devices
|
US8697844B2
(en)
*
|
2009-11-24 |
2014-04-15 |
Novo Nordisk A/S |
Method of purifying pegylated proteins
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
US20110165155A1
(en)
*
|
2009-12-04 |
2011-07-07 |
Genentech, Inc. |
Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
|
WO2011073389A1
(en)
|
2009-12-18 |
2011-06-23 |
Novartis Ag |
Wash solution and method for affinity chromatography
|
EP2536748B1
(de)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin-antagonisten und ihre verwendung zur behandlung von krebs
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
KR101152036B1
(ko)
*
|
2010-04-27 |
2012-06-08 |
(주)셀트리온 |
컬럼 순환 및 시료 연속주입법을 이용한 단백질 a 크로마토그래피 정제 방법
|
JP5947289B2
(ja)
|
2010-05-10 |
2016-07-06 |
アカデミア シニカAcademia Sinica |
抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
|
CN103038247A
(zh)
*
|
2010-05-18 |
2013-04-10 |
Abbvie公司 |
蛋白质提纯的装置和方法
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
NZ603648A
(en)
*
|
2010-05-25 |
2014-12-24 |
Genentech Inc |
Methods of purifying polypeptides
|
MX339809B
(es)
*
|
2010-05-27 |
2016-06-09 |
Merck Sharp & Dohme Corp * |
Metodo para preparar anticuerpos con propiedades mejoradas.
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
GB201012603D0
(en)
*
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Protein purification
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
PE20140229A1
(es)
|
2010-08-26 |
2014-03-27 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CA2845395A1
(en)
*
|
2010-09-01 |
2013-03-08 |
Bio Matrix Research, Inc. |
Antibody against colorectal cancer marker
|
EA201300418A1
(ru)
|
2010-10-05 |
2013-09-30 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к человеческому tweak и варианты их применения
|
US20120264920A1
(en)
*
|
2010-10-11 |
2012-10-18 |
Abbott Laboratories |
Processes for purification of proteins
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
EP2649087A1
(de)
*
|
2010-12-08 |
2013-10-16 |
Amgen Inc. |
Ionenaustauschchromatografie in gegenwart einer aminosäure
|
MX357821B
(es)
|
2010-12-21 |
2018-07-25 |
Hoffmann La Roche |
Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CA2828746C
(en)
*
|
2011-03-03 |
2019-05-07 |
Arla Foods Amba |
Method for isolating osteopontin using concentrated feeds
|
EP2686016B1
(de)
|
2011-03-14 |
2019-05-01 |
Cellmid Limited |
Antikörper zur erkennung der n-domäne von midkin
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
JP6187777B2
(ja)
|
2011-06-13 |
2017-08-30 |
シーエスエル、リミテッド |
G−csfrに対する抗体およびその使用
|
JP2014526891A
(ja)
|
2011-08-17 |
2014-10-09 |
ジェネンテック, インコーポレイテッド |
ニューレグリン抗体とその使用
|
WO2013050335A1
(en)
|
2011-10-05 |
2013-04-11 |
F. Hoffmann-La Roche Ag |
Process for antibody g1 glycoform production
|
DK2766040T3
(da)
|
2011-10-14 |
2019-07-22 |
Hoffmann La Roche |
Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
US20140288278A1
(en)
*
|
2011-10-31 |
2014-09-25 |
Joseph Nti-Gyabaah |
Chromatography process for resolving heterogeneous antibody aggregates
|
CA2854330A1
(en)
*
|
2011-11-02 |
2013-05-10 |
Genentech, Inc. |
Overload and elute chromatography
|
RU2019103083A
(ru)
|
2011-11-30 |
2019-03-22 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
AU2012362326A1
(en)
|
2011-12-30 |
2014-07-24 |
Abbvie Inc. |
Dual variable domain immunoglobulins against IL-13 and/or IL-17
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP3505534A1
(de)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
ES2611788T3
(es)
*
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
WO2014118685A2
(en)
*
|
2013-01-29 |
2014-08-07 |
Dr. Reddy's Laboratories Limited |
Method of altering the acidic variant content of antibody
|
AU2014214530B2
(en)
|
2013-02-07 |
2014-10-16 |
Csl Limited |
IL-11R binding proteins and uses thereof
|
WO2014137903A2
(en)
|
2013-03-08 |
2014-09-12 |
Genzyme Corporation |
Integrated continuous manufacturing of therapeutic protein drug substances
|
AU2013381687A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
JP6285532B2
(ja)
|
2013-03-14 |
2018-02-28 |
イー・エム・デイー・ミリポア・コーポレイシヨン |
タンパク質aに基づくクロマトグラフィを使用するタンパク質純度を増加させる方法
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014144600A2
(en)
|
2013-03-15 |
2014-09-18 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
BR112015024926A2
(pt)
|
2013-04-16 |
2017-10-10 |
Genentech Inc |
composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
|
AR096713A1
(es)
|
2013-06-25 |
2016-01-27 |
Cadila Healthcare Ltd |
Proceso de purificación para anticuerpos monoclonales
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
US9764039B2
(en)
*
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
CA2918052A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
KR102298172B1
(ko)
|
2013-09-06 |
2021-09-06 |
아카데미아 시니카 |
변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
|
EP3048109A4
(de)
*
|
2013-09-17 |
2017-04-19 |
Kaneka Corporation |
Neuartiges antikörperaufreinigungsverfahren und antikörper daraus sowie neuartiges antikörperaufreinigungsverfahren unter verwendung eines kationenaustauschers und antikörper daraus
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
WO2015056237A2
(en)
*
|
2013-10-18 |
2015-04-23 |
Universität Für Bodenkultur Wien |
Purification of proteins
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
WO2015064971A1
(ko)
*
|
2013-10-30 |
2015-05-07 |
(주)셀트리온 |
양이온 교환 크로마토그래피를 이용한 항체의 아형 분리 방법
|
CN104628846B
(zh)
*
|
2013-11-06 |
2019-12-06 |
三生国健药业(上海)股份有限公司 |
重组蛋白质的纯化方法
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TWI709569B
(zh)
|
2014-01-17 |
2020-11-11 |
美商健臻公司 |
無菌層析樹脂及其用於製造方法的用途
|
TWI709570B
(zh)
|
2014-01-17 |
2020-11-11 |
美商健臻公司 |
無菌層析法及製法
|
EP3129767B1
(de)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reaktive markierungsverbindungen und ihre verwendungen
|
SG10201809411PA
(en)
|
2014-04-25 |
2018-11-29 |
Genentech Inc |
Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184002A1
(en)
*
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
CN107074945B
(zh)
|
2014-05-27 |
2021-08-24 |
中央研究院 |
增进抗体功效的通用糖型的组合物及方法
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
SG11201610431WA
(en)
*
|
2014-06-25 |
2017-01-27 |
Jhl Biotech Inc |
Methods and reagents for purification of proteins
|
CN105315369B
(zh)
*
|
2014-07-25 |
2020-03-13 |
山东博安生物技术有限公司 |
利用阳离子交换层析纯化蛋白质
|
WO2016033245A1
(en)
|
2014-08-26 |
2016-03-03 |
Rmx, Llc |
Devices and methods for reducing intrathoracic pressure
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
JP2021006540A
(ja)
*
|
2014-09-10 |
2021-01-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ガラクトース操作型免疫グロブリン1抗体
|
EP3191527B1
(de)
|
2014-09-10 |
2020-01-15 |
F.Hoffmann-La Roche Ag |
Durch in-vitro-galaktoengineering hergestellte immunglobulin-1-antikörper
|
SG10201809668TA
(en)
|
2014-09-12 |
2018-11-29 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
CN107124870A
(zh)
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
WO2016071376A2
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
KR101531479B1
(ko)
*
|
2014-11-21 |
2015-06-26 |
세원셀론텍(주) |
의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
CN110658340B
(zh)
*
|
2015-01-08 |
2023-10-31 |
苏州康宁杰瑞生物科技有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
US10538596B2
(en)
|
2015-01-09 |
2020-01-21 |
Adalta Limited |
CXCR4 binding molecules and methods of use thereof
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016118707A1
(en)
*
|
2015-01-21 |
2016-07-28 |
Oncobiologics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
JP6807859B2
(ja)
*
|
2015-03-13 |
2021-01-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
クロマトグラフィーにおける不純物を取り除くためのアルカリ洗浄の使用
|
CN107614015A
(zh)
|
2015-05-30 |
2018-01-19 |
豪夫迈·罗氏有限公司 |
治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
|
EP3307780A1
(de)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antikörper und immunkonjugate
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
PL3319995T3
(pl)
|
2015-07-07 |
2019-09-30 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
CN108350026A
(zh)
*
|
2015-11-18 |
2018-07-31 |
默克专利股份公司 |
离子交换色谱法中改进的蛋白质分离
|
BR112018009882A2
(pt)
*
|
2015-11-18 |
2018-11-13 |
Merck Patent Gmbh |
gradientes de ph-sal opostos para separações melhoradas de proteína
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
AU2017213775A1
(en)
|
2016-02-03 |
2018-08-16 |
Outlook Therapeutics, Inc. |
Buffer formulations for enhanced antibody stability
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
CN109415427A
(zh)
*
|
2016-07-15 |
2019-03-01 |
豪夫迈·罗氏有限公司 |
用于纯化聚乙二醇化的促红细胞生成素的方法
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
MX2019003563A
(es)
|
2016-09-29 |
2019-08-12 |
Beijing Hanmi Pharmaceutical Co Ltd |
Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas.
|
KR20190075114A
(ko)
|
2016-11-04 |
2019-06-28 |
제넨테크, 인크. |
Her2-양성 유방암의 치료
|
TN2019000161A1
(en)
*
|
2016-11-18 |
2020-10-05 |
Beijing Hanmi Pharmaceutical Co Ltd |
Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
|
EP3562844A1
(de)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Behandlung von fortgeschrittenem her2-exprimierendem krebs
|
EP3570884B1
(de)
|
2017-01-17 |
2020-09-30 |
Genentech, Inc. |
Subkutane her2-antikörperformulierungen
|
WO2018160654A2
(en)
|
2017-03-02 |
2018-09-07 |
Genentech, Inc. |
Adjuvant treatment of her2-positive breast cancer
|
EP3615695A1
(de)
|
2017-04-24 |
2020-03-04 |
Genentech, Inc. |
Erbb2/her2-mutationen in der transmembran- oder juxtamembran-domäne
|
CN107602702A
(zh)
|
2017-09-22 |
2018-01-19 |
生标(上海)医疗器械科技有限公司 |
一种同时靶向人p185和血管内皮生长因子的抗体及其应用
|
CN108101987A
(zh)
*
|
2017-11-17 |
2018-06-01 |
安徽未名生物医药有限公司 |
一种重组抗TNF-α全人源单克隆抗体的纯化方法
|
DK3717011T3
(da)
|
2017-11-29 |
2023-01-09 |
Csl Ltd |
Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
CN111655731A
(zh)
|
2018-03-13 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
AR114722A1
(es)
|
2018-04-02 |
2020-10-07 |
Amgen Inc |
Composiciones de erenumab y usos de las mismas
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
KR20210049155A
(ko)
|
2018-08-31 |
2021-05-04 |
젠자임 코포레이션 |
멸균 크로마토그래피 수지 및 제조 공정에서 이의 용도
|
WO2020047345A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
HRP20221517T1
(hr)
|
2018-10-15 |
2023-02-17 |
F. Hoffmann - La Roche Ag |
Postupci za liječenje rezidualnog raka dojke s trastuzumab emtanzinom
|
CN111196856A
(zh)
*
|
2018-11-19 |
2020-05-26 |
三生国健药业(上海)股份有限公司 |
抗her2/pd1双特异性抗体
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
WO2020234742A1
(en)
|
2019-05-20 |
2020-11-26 |
Lupin Limited |
Granulocyte colony stimulating factor purification
|
US20200390899A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
US11266838B1
(en)
|
2019-06-21 |
2022-03-08 |
Rmx, Llc |
Airway diagnostics utilizing phrenic nerve stimulation device and method
|
CN110339209B
(zh)
*
|
2019-07-18 |
2023-06-06 |
上海泰坦科技股份有限公司 |
一种去甲状腺结合蛋白的小牛血清的制备方法
|
US20220313835A1
(en)
|
2019-09-03 |
2022-10-06 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
WO2021067242A1
(en)
|
2019-09-30 |
2021-04-08 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
CN114599971A
(zh)
*
|
2019-10-14 |
2022-06-07 |
皮尔斯生物科技有限公司 |
肽纯化配制物和方法
|
BR112022007719A2
(pt)
|
2019-10-25 |
2022-07-12 |
Bolt Biotherapeutics Inc |
Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
|
KR20220115566A
(ko)
|
2019-11-15 |
2022-08-17 |
시아겐 인크. |
항-her2 항체-약물 접합체와 조합된 투카티닙으로 her2 양성 유방암을 치료하는 방법
|
AU2020404453B2
(en)
|
2019-12-20 |
2022-12-08 |
Hudson Institute of Medical Research |
CXCL10 binding proteins and uses thereof
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
US20220017637A1
(en)
|
2020-06-23 |
2022-01-20 |
Hoffmann-La Roche Inc. |
Agonistic cd28 antigen binding molecules targeting her2
|
CN115916834A
(zh)
|
2020-06-29 |
2023-04-04 |
基因泰克公司 |
帕妥珠单抗加曲妥珠单抗的固定剂量组合
|
KR20230037560A
(ko)
|
2020-07-14 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
고정 용량 조합에 대한 분석
|
EP4182475A2
(de)
|
2020-07-17 |
2023-05-24 |
Onena Medicines S.L. |
Antikörper gegen linksprotein
|
CN116234586A
(zh)
|
2020-08-13 |
2023-06-06 |
博尔特生物治疗药物有限公司 |
吡唑并氮呯免疫缀合物及其用途
|
CN112430252B
(zh)
*
|
2020-11-13 |
2022-09-02 |
宜昌东阳光长江药业股份有限公司 |
一种提高目标蛋白回收率的层析方法
|
CA3200320A1
(en)
|
2020-12-11 |
2022-06-16 |
Shelley Erin ACKERMAN |
Anti-her2 immunoconjugates, and uses thereof
|
WO2022125904A1
(en)
|
2020-12-11 |
2022-06-16 |
Bolt Biotherapeutics, Inc. |
Anti-her2 immunoconjugates, and uses thereof
|
EP4259662A1
(de)
|
2020-12-11 |
2023-10-18 |
Genentech, Inc. |
Kombinationstherapien zur behandlung von her2-krebs
|
TW202300175A
(zh)
|
2021-03-26 |
2023-01-01 |
美商博特生物治療公司 |
2-胺基-4-羧醯胺-苯并氮呯免疫結合物及其用途
|
CN117769439A
(zh)
|
2021-03-26 |
2024-03-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
|
AR125258A1
(es)
|
2021-04-01 |
2023-06-28 |
Vestaron Corp |
Polipéptidos con mutaciones de av3 para el control de plagas
|
CN113769794B
(zh)
*
|
2021-07-06 |
2024-04-05 |
沁浩膜技术(厦门)有限公司 |
一种连续脱除胞磷胆碱钠中杂质的离子交换系统及方法
|
CA3234604A1
(en)
|
2021-10-29 |
2023-05-04 |
Shelley Erin ACKERMAN |
Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
|
WO2023122805A1
(en)
|
2021-12-20 |
2023-06-29 |
Vestaron Corporation |
Sorbitol driven selection pressure method
|
CN114230641B
(zh)
*
|
2021-12-29 |
2024-03-26 |
内蒙古必威安泰生物科技有限公司 |
一种去除口蹄疫抗原液中内毒素的方法
|
WO2023192924A1
(en)
|
2022-03-30 |
2023-10-05 |
Vestaron Corporation |
Combinations of av3 mutant polypeptides and bt toxins for pest control
|
WO2023225555A1
(en)
|
2022-05-18 |
2023-11-23 |
Vestaron Corporation |
Pesticidal actx peptide variants
|
WO2023245100A1
(en)
|
2022-06-17 |
2023-12-21 |
Vestaron Corporation |
Antimicrobial ncr13 variant peptides
|
WO2024026406A2
(en)
|
2022-07-29 |
2024-02-01 |
Vestaron Corporation |
Next Generation ACTX Peptides
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038198A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|